321 related articles for article (PubMed ID: 30014885)
1. Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
Gelli M; Huguenin JFL; de Baere T; Benhaim L; Mariani A; Boige V; Malka D; Sourouille I; Ducreux M; Elias D; Goéré D
Eur J Cancer; 2018 Sep; 100():94-103. PubMed ID: 30014885
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
3. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
5. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
6. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience.
Alzahrani NA; Valle SJ; Fisher OM; Sugarbaker PH; Yonemura Y; Glehen O; Goere D; Honore C; Brigand C; de Hingh I; Verwaal VJ; Deraco M; Baratti D; Kusamura S; Pocard M; Piso P; Maerz L; Marchal F; Moran B; Levine EA; Dumont F; Pezet D; Abboud K; Kozman MA; Liauw W; Morris DL;
J Surg Oncol; 2019 Mar; 119(3):336-346. PubMed ID: 30554404
[TBL] [Abstract][Full Text] [Related]
7. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
[TBL] [Abstract][Full Text] [Related]
8. Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM).
Larentzakis A; O'Dwyer ST; Becker J; Shuweihdi F; Aziz O; Selvasekar CR; Fulford P; Renehan AG; Wilson M
Eur J Surg Oncol; 2019 Dec; 45(12):2310-2315. PubMed ID: 31433300
[TBL] [Abstract][Full Text] [Related]
9. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
Saxena A; Valle SJ; Liauw W; Morris DL
Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
[TBL] [Abstract][Full Text] [Related]
10. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
12. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.
Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB
Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834
[TBL] [Abstract][Full Text] [Related]
13. Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis.
Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
Ann Surg Oncol; 2015 Aug; 22(8):2656-62. PubMed ID: 25515200
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
Ihemelandu C; Mavros MN; Sugarbaker P
Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
[TBL] [Abstract][Full Text] [Related]
17. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U
Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I
Trials; 2010 May; 11():62. PubMed ID: 20500867
[TBL] [Abstract][Full Text] [Related]
19. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
Wong JF; Tan GH; Wang W; Soo KC; Teo MC
World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases.
Tonello M; Ortega-Perez G; Alonso-Casado O; Torres-Mesa P; Guiñez G; Gonzalez-Moreno S
Clin Transl Oncol; 2018 Oct; 20(10):1268-1273. PubMed ID: 29667123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
